Today: 29 April 2026
Browse Category

LSE:GSK.L 28 November 2025 - 2 March 2026

Why GSK stock is moving today: Exdensur EU nod and a fresh buyback

Why GSK stock is moving today: Exdensur EU nod and a fresh buyback

GSK shares rose 1.1% to 2,263 pence after the European Commission approved its twice-yearly asthma drug Exdensur and the company launched a new tranche of share buybacks. GSK will repurchase up to £0.45 billion in shares by April 24. The company also reported new real-world data showing its RSV vaccine Arexvy was 75.6% effective against RSV-related hospitalisation in adults over 60.
18 February 2026
··
GSK stock price in focus before London open after China starts Arexvy review

GSK stock price in focus before London open after China starts Arexvy review

China’s Center for Drug Evaluation has accepted GSK’s Arexvy RSV vaccine application for review, with a decision expected in 2027. GSK shares closed Tuesday up 0.42% at 2,168 pence ahead of the London open. JPMorgan raised its target price to £22.50, and the company’s next dividend goes ex-dividend on Feb. 19. Non-executive director Hal Barron sold 67,602 ADSs at $59.17 on Feb. 5.
11 February 2026
·
GSK stock slips in London as hepatitis B drug details awaited; Feb 4 results loom

GSK stock slips in London as hepatitis B drug details awaited; Feb 4 results loom

GSK shares slipped 0.6% to 1,879.5p in London by 10:50 GMT as investors awaited detailed data from its phase III hepatitis B drug trial. Analysts pressed for cure rate and durability figures after GSK withheld specifics. A royalty dispute over cancer drug Jemperli is pending in U.S. court, with a trial set for July 2026. Investors are watching for updates at the Jan. 13 J.P. Morgan conference and Feb. 4 results.
9 January 2026
···
Most Active UK Stocks Today (9 December 2025): BP, Barclays, Rolls‑Royce, Unilever and More in Focus

Most Active UK Stocks Today (9 December 2025): BP, Barclays, Rolls‑Royce, Unilever and More in Focus

The FTSE 100 closed down 0.2% at 9,645.09 on Monday, with heavy trading concentrated in BP, Barclays, Rolls-Royce, Unilever, Lloyds, HSBC, London Stock Exchange Group, Anglo American, GSK, and British American Tobacco. Investors pulled back ahead of key US Federal Reserve and Bank of England rate decisions. FTSE 100 futures hovered near 9,657 early Tuesday, with technical signals pointing to caution.
9 December 2025
···········
Best UK Stocks to Buy Today (8 December 2025): 7 FTSE 100 Ideas for a Potential Rate‑Cut Era

Best UK Stocks to Buy Today (8 December 2025): 7 FTSE 100 Ideas for a Potential Rate‑Cut Era

The FTSE 100 closed near 9,660 on December 8, posting a total return of about 20–23% year-to-date, its best run since 2009. The Bank of England has held rates at 4% since August, with inflation at 3.6%. Markets expect a rate cut to 3.75% at the December 18 meeting. UK mortgage rates have dropped to their lowest since before September 2022.
8 December 2025
·········
GSK plc Stock Today, 28 November 2025: Buybacks, ‘Hold’ Ratings and Pipeline Momentum Keep Shares Near Highs

GSK plc Stock Today, 28 November 2025: Buybacks, ‘Hold’ Ratings and Pipeline Momentum Keep Shares Near Highs

GSK shares traded near 12-month highs on November 28, 2025, with London shares at 1,806p, up 0.2%, and New York ADRs at $48.02, just below their yearly peak. MarketBeat issued a fresh “Hold” consensus from seven analysts, with an average 12-month price target of $44.13, under current levels. The stock’s recent gains follow continued share buybacks and a busy drug pipeline.
28 November 2025
··

Stock Market Today

  • Greatland Resources (ASX:GGP) Rises 44.6% in a Month but Valuation Suggests Undervaluation
    April 29, 2026, 3:04 AM EDT. Greatland Resources (ASX:GGP) surged 44.6% over the past month, closing at A$14.11 despite a recent 3% weekly dip. The stock's year-to-date gain stands at 33.6%. Analysts highlight its discounted cash flow (DCF) valuation, indicating the stock could be undervalued by 62%, with a DCF-implied fair value of A$37.17 per share versus the current price. The DCF model projects growing free cash flows to equity, reaching over A$2 billion by 2035. Yet, the stock delivered 0% returns over the last year, reflecting mixed performance within the metals and mining sector. Investors debate whether the recent rally reflects momentum or if the stock remains attractively priced relative to peers. This volatility underscores shifting risk sentiment and the importance of valuation metrics in market reassessment.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 29.04.2026

29 April 2026
LIVEMarkets rolling coverageStarted: April 29, 2026, 12:00 AM EDTUpdated: April 29, 2026, 3:04 AM EDT Greatland Resources (ASX:GGP) Rises 44.6% in a Month but Valuation Suggests Undervaluation April 29, 2026, 3:04 AM EDT. Greatland Resources (ASX:GGP) surged 44.6% over the past month, closing at A$14.11 despite a recent 3% weekly dip. The stock's year-to-date gain stands at 33.6%. Analysts highlight its discounted cash flow (DCF) valuation, indicating the stock could be undervalued by 62%, with a DCF-implied fair value of A$37.17 per share versus the current price. The DCF model projects growing free cash flows to equity, reaching over A$2
AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
Go toTop